Cytokinetics (NASDAQ:CYTK – Get Free Report) is scheduled to be releasing its earnings data after the market closes on Wednesday, November 6th. Analysts expect Cytokinetics to post earnings of ($1.26) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Cytokinetics (NASDAQ:CYTK – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.25). The firm had revenue of $0.25 million during the quarter, compared to the consensus estimate of $7.61 million. During the same period in the previous year, the business earned ($1.34) EPS. The business’s revenue was down 71.3% on a year-over-year basis. On average, analysts expect Cytokinetics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Cytokinetics Price Performance
Shares of NASDAQ:CYTK opened at $51.51 on Wednesday. Cytokinetics has a one year low of $30.68 and a one year high of $110.25. The stock has a fifty day moving average of $54.61 and a 200-day moving average of $56.27. The company has a market capitalization of $6.06 billion, a PE ratio of -9.59 and a beta of 0.77. The company has a debt-to-equity ratio of 5.93, a quick ratio of 10.39 and a current ratio of 10.39.
Insider Activity
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the company. JMP Securities restated a “market outperform” rating and issued a $78.00 target price on shares of Cytokinetics in a report on Wednesday, September 4th. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of Cytokinetics in a report on Thursday, October 17th. Needham & Company LLC reiterated a “buy” rating and set a $72.00 price objective on shares of Cytokinetics in a report on Thursday, October 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a report on Friday, October 18th. Finally, The Goldman Sachs Group lowered Cytokinetics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $85.00 to $60.00 in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $83.93.
Get Our Latest Stock Report on CYTK
Cytokinetics Company Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Recommended Stories
- Five stocks we like better than Cytokinetics
- What is Insider Trading? What You Can Learn from Insider Trading
- 2 Small Modular Reactor Stocks Racing to Power AI Data Centers
- How to Use the MarketBeat Stock Screener
- Oklo Stock: Nuclear Powerhouse or Radioactive Hype?
- Want to Profit on the Downtrend? Downtrends, Explained.
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.